Anavex Life Sciences Corp (AVXL)

[boi568]

The EMA clearly was not bothered by the lack of a second trial. Why else would it then devote its time and resources to a year long and broader review of blarcamesine when it was doomed to be rejected for such an obvious fatal flaw? How could it achieve such a high approval MAA approval rate if its acceptance standards were so low? Again, too stupid to imagine.

I have noticed that as the facts have turned more and more favorable for longs, Investor's and other's predictions of certain doom have become ludicrous.